We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From JAMA |

Clusterin as an Alzheimer Biomarker

John Hardy, PhD; Rita Guerreiro, MS, PhD; Simon Lovestone, PhD, MRCPsych
Arch Neurol. 2011;68(11):1459-1460. doi:10.1001/archneurol.2011.1000.
Text Size: A A A
Published online


In a remarkable series of little-noticed studies, May et al1 and Poirier et a12 carried out entorhinal lesions in adult rats to see which genes were acutely upregulated. Their reasoning was that such response genes would be candidate genes for Alzheimer disease. Remarkably, they picked out just 2 genes: apolipoprotein E (ApoE) and clusterin (Clu ; apolipoprotein J). While APOE was shown to be a locus for Alzheimer disease within a couple years,3 the realization that CLU was a locus for the disease was made only with the advent of genome-wide association studies4 clearly documenting that genetic variability at the locus contributed to risk. Unlike APOE, where the major (but not the only) risk is encoded by protein coding change,5 in CLU there is not a common coding variant in European populations even though there are a lot of rare variants.6 Rather, it seems that genetic variability in expression is the underlying reason the CLU locus appears as a risk locus for disease. This genetic variability in expression does not relate to the resting expression of this reactive protein (which is not different based on genotype), but rather most likely relates to genetic variability in damage response expression.6


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.